Bionano Genomics, Inc. BNGO
We take great care to ensure that the data presented and summarized in this overview for Bionano Genomics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BNGO
View allLatest Institutional Activity in BNGO
Top Purchases
Top Sells
About BNGO
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Insider Transactions at BNGO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 11
2024
|
Mark Oldakowski Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,568
-5.5%
|
$0
$0.48 P/Share
|
Sep 11
2024
|
Alka Chaubey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,075
-6.35%
|
$0
$0.48 P/Share
|
Jun 03
2024
|
Gulsen Kama Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
Jun 03
2024
|
Mark Oldakowski Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+19.83%
|
-
|
Jun 03
2024
|
Alka Chaubey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+24.9%
|
-
|
Jun 03
2024
|
Jonathan V. Dixon GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+44.58%
|
-
|
Jun 03
2024
|
R. Erik Holmlin PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+26.54%
|
-
|
Feb 15
2024
|
Jonathan V. Dixon GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
402
-10.24%
|
$402
$1.27 P/Share
|
Feb 15
2024
|
R. Erik Holmlin PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,073
-3.81%
|
$3,073
$1.27 P/Share
|
Feb 15
2024
|
Mark Oldakowski Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,229
-2.46%
|
$1,229
$1.27 P/Share
|
Feb 15
2024
|
Alka Chaubey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,081
-3.32%
|
$1,081
$1.27 P/Share
|
Sep 18
2023
|
Mark Oldakowski Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+5.92%
|
-
|
Sep 18
2023
|
Alka Chaubey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+12.14%
|
-
|
Jun 13
2023
|
Hannah Mamuszka Director |
BUY
Open market or private purchase
|
Direct |
65,789
+50.0%
|
$0
$0.76 P/Share
|
May 16
2023
|
R. Erik Holmlin PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
15,000
+1.83%
|
$0
$0.64 P/Share
|
May 12
2023
|
Mark Oldakowski Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,496
-12.23%
|
$0
$0.66 P/Share
|
May 12
2023
|
Christopher P. Stewart Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+15.09%
|
$0
$0.67 P/Share
|
May 12
2023
|
R. Erik Holmlin PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
50,141
-5.96%
|
$0
$0.66 P/Share
|
Feb 15
2023
|
Christopher P. Stewart Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+31.22%
|
-
|
Feb 15
2023
|
Alka Chaubey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+49.02%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 107K shares |
---|
Payment of exercise price or tax liability | 12.4K shares |
---|